Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Efavirenz Teva

Efavirenz Teva 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12

HOS-215282 · Präparat HOS-155418

11 Medicinal product by Effects on drug levels Recommendation concerning therapeutic areas Mean percent change in AUC, co-administration with (dose) Cmax, Cmin with confidence efavirenz intervals if availablea (mechanism) Velpatasvir/sofosbuvir/voxilap ↓velpatasvir Concomitant administration of revir ↓voxilaprevir velpatasvir/sofosbuvir/ voxilaprevir with efavirenz is not recommended, as it may decrease concentrations of velpatasvir and voxilaprevir. Refer to the prescribing information for velpatasvir/sofosbuvir/ voxilaprevir for more information. Protease inhibitor : ↓elbasvir Concomitant administration of Elbasvir/grazoprevir ↓grazoprevir efavirenz with elbasvir/grazoprevir is ↔efavirenz contraindicated because it may lead to loss of virologic response to elbasvir/grazoprevir. This loss is due to significant decreases in elbasvir and grazoprevir plasma concentrations caused by CYP3A4 induction. Refer to the prescribing information for elbasvir/grazoprevir for more information. Glecaprevir/pibrentasvir ↓glecaprevir Concomitant administration of ↓ pibrentasvir glecaprevir/pibrentasvir with efavirenz may significantly decrease plasma concentrations of glecaprevir and pibrentasvir, leading to reduced therapeutic effect. Coadministration of glecaprevir/pibrentasvir with efavirenz is not recommended. Refer to the prescribing information for glecaprevir/pibrentasvir for more information. Antibiotics Azithromycin/efavirenz No clinically significant No dose adjustment is necessary (600 mg single dose/400 mg once pharmacokinetic interaction for either medicinal product. daily) Clarithromycin/efavirenz Clarithromycin: The clinical significance of these (500 mg q12h/400 mg once daily) AUC: ↓ 39% (↓ 30 to ↓ 46) changes in clarithromycin plasma Cmax: ↓ 26% (↓ 15 to ↓ 35) levels is not known. Alternatives to clarithromycin (e.g. Clarithromycin azithromycin) may be considered. 14-hydroxymetabolite: No dose adjustment is necessary AUC: ↑ 34% (↑ 18 to ↑ 53) for efavirenz. Cmax: ↑ 49% (↑ 32 to ↑ 69)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) sofosbuvir (HOS-108928) protease (HOS-085623) pibrentasvir (HOS-086298) glecaprevir (HOS-086297) azithromycin (HOS-088112) lead (HOS-085592) voxilaprevir (HOS-108930) grazoprevir (HOS-108815) clarithromycin (HOS-084517) velpatasvir (HOS-108929)